S9630, Medroxyprogesterone in Treating Women With Breast Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing
endometrial disorder in patients with breast cancer who are taking tamoxifen.
PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in
preventing endometrial disorder in postmenopausal women who have ductal carcinoma in situ,
lobular carcinoma in situ, Paget's disease of the nipple, stage I breast cancer, or stage II
breast cancer and who are taking tamoxifen.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Cancer and Leukemia Group B National Cancer Institute (NCI)